Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 19, 2019 - Issue 6
Submit an article Journal homepage
728
Views
12
CrossRef citations to date
0
Altmetric
Review

Cost burden of diffuse large B-cell lymphoma

R. Andrew HarkinsDepartment of Medicine, Emory University School of Medicine, Atlanta, GA, USAView further author information
,
Sharvil P. PatelDepartment of Quantitative Theories and Methods, Emory University, Atlanta, GA, USAView further author information
&
Christopher R. FlowersDepartment of Hematology and Oncology, Winship Research Informatics Shared Resource Emory University School of Medicine Winship Cancer Institute, Atlanta, GA, USACorrespondence[email protected]
View further author information
Pages 645-661 | Received 30 Jun 2019, Accepted 11 Oct 2019, Published online: 22 Oct 2019

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

R. Andrew Harkins & Christopher R. Flowers. (2020) How should clinicians interpret conflicting cost-effectiveness analyses for the treatment of lymphoma across nations and payer models?. Leukemia & Lymphoma 61:14, pages 3283-3286.
Read now

Articles from other publishers (11)

John M. Burke, Anthony Masaquel, Rongrong Wang, Farah Hossain, Jia Li, Summera Qiheng Zhou, Carmen D. Ng & Matthew Matasar. (2023) Cost of Disease Progression in Diffuse Large B-Cell Lymphoma After Frontline Treatment With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. Clinical Lymphoma Myeloma and Leukemia 23:11, pages e393-e404.
Crossref
Christopher Hino, Curtis Lacy, Joel Brothers, Huynh Cao, Hamid Mirshahidi, Kiwon Park & Mojtaba Akhtari. (2023) Factors Influencing Physician Discretion to Administer CNS Prophylaxis in Diffuse Large B Cell Lymphoma: A Single Institution Retrospective Study. Clinical Lymphoma Myeloma and Leukemia.
Crossref
Jingwen Jiang, Yanjuan Huang, Zishan Zeng & Chunshun Zhao. (2023) Harnessing Engineered Immune Cells and Bacteria as Drug Carriers for Cancer Immunotherapy. ACS Nano 17:2, pages 843-884.
Crossref
Juan Pablo Alderuccio & Jeff P. Sharman. (2022) ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma. Blood Reviews 56, pages 100967.
Crossref
Bernhard Moertl, Martin Dreyling, Christian Schmidt, Eva Hoster, Wolfgang Schoel, Michael v. Bergwelt-Baildon & Karin Berger. (2022) Inpatient treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): A health economic perspective. Clinical Lymphoma Myeloma and Leukemia 22:7, pages 474-482.
Crossref
Julia Thornton Snider, Donna McMorrow, Xue Song, David Diakun, Sally W. Wade & Paul Cheng. (2022) Burden of Illness and Treatment Patterns in Second-line Large B-cell Lymphoma. Clinical Therapeutics 44:4, pages 521-538.
Crossref
Hatice TERZİ, Kübra ORAL, Hüseyin YILMAZ, Ecem DEMİR YURTSEVEN & Mehmet ŞENCAN. (2022) SINGLE-CENTER EXPERIENCE IN RELAPSED/REFRACTORY NON-HODGKIN’S LYMPHOMA (RELAPS/REFRAKTER NON HODGKİN LENFOMALARDA TEK MERKEZ DENEYİMİ). Cumhuriyet Medical Journal.
Crossref
Virginie Nerich, Christophe Guyeux, Michel Henry‐Amar, Raphaël Couturier, Catherine Thieblemont, Vincent Ribrag, Hervé Tilly, Corinne Haioun, René‐Olivier Casasnovas, Franck Morschhauser, Pierre Feugier, David Sibon, Loic Ysebaert, Emmanuelle Nicolas‐Virelizier, Florence Broussais‐Guillaumot, Gandhi L. Damaj, Jean‐Philippe Jais, Gilles Salles, Macha Woronoff‐Lemsi & Nicolas Mounier. (2021) Economic burden in non‐Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross‐sectional study. Cancer 128:3, pages 519-528.
Crossref
Bushra Kanwal. (2021) Relapsed/Refractory Non-Hodgkin Lymphoma: Engineering T-Cells to Express Chimeric Antigen Receptors (CARs), a Salvage?. Cureus.
Crossref
Jonathan S. Rink, Adam Yuh Lin, Kaylin M. McMahon, Andrea E. Calvert, Shuo Yang, Tim Taxter, Jonathan Moreira, Amy Chadburn, Amir Behdad, Reem Karmali, C. Shad Thaxton & Leo I. Gordon. (2021) Targeted reduction of cholesterol uptake in cholesterol-addicted lymphoma cells blocks turnover of oxidized lipids to cause ferroptosis. Journal of Biological Chemistry 296, pages 100100.
Crossref
Omran Saifi, Mohamed A. Kharfan-Dabaja, Youssef H. Zeidan, Jennifer Peterson, William G. Rule, Scott C. Lester & Bradford S. Hoppe. (2020) Proton Therapy as a Bridging Treatment in CAR T-Cell Therapy for Relapsed and Refractory Large B-Cell Lymphoma: Is There a Role?. International Journal of Particle Therapy 7:1, pages 13-20.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.